Develops and commercializes therapies targeting neurological disorders, with a historical focus on treatments for multiple sclerosis and other conditions affecting the nervous system. The company has generated revenue from Ampyra (dalfampridine), a therapy designed to improve walking in people with ...
No congressional trades have been disclosed for Acorda Inc. (ACOR) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.